TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

SKYE Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the Skye Bioscience, Inc. Class Action Lawsuit

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Robbins Llp
SKYE Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the Skye Bioscience, Inc. Class Action Lawsuit

Skye Bioscience faces a class action lawsuit alleging misleading investors about its lead drug candidate nimacimab's effectiveness, with stock price dropping 60% after revealing poor clinical trial results.

Insights
SKYE   negative

Stock price fell 60% after revealing that drug candidate did not achieve primary weight loss endpoint, suggesting potential failure of key product and potential investor deception